Send to

Choose Destination
See comment in PubMed Commons below
Rev Med Interne. 2013 Sep;34(9):553-60. doi: 10.1016/j.revmed.2012.12.020. Epub 2013 Aug 5.

[Large granular lymphocyte leukemia: clinical and pathogenic aspects].

[Article in French]

Author information

Service de médecine interne, hôpital du Haut Lévêque, avenue Magellan, 33604 Pessac, France.


Large granular lymphocyte leukemia (LGL) is a hematologic disorder characterized by a monoclonal expansion of large lymphocytes containing azurophilic granules with a T CD3(+)CD57(+) or Natural Killer (NK) CD3(-)CD56(+) phenotype. The World Health Organization (WHO) classification identifies three entities: the T LGL, the chronic lymphoproliferative disorder of NK-cells, and the aggressive NK-cell leukemia. T LGL and chronic lymphoproliferative disorder of NK-cells are indolent diseases frequently associated with cytopenias and a wide spectrum of auto-immune manifestations. Neutropenia can lead to recurrent bacterial infections, which represent an indication of initiating a treatment in most of the cases. Immunosuppressive therapies are usually used in this context. In contrast, aggressive NK-cell leukemia follows a fulminant course with a poor prognosis because patients are refractory to most of the treatments. There is now a considerable interest in the pathophysiology of the disease with the perspective of new therapeutic options.


Cytopenia; Cytopénie; Felty's syndrome; Large granular lymphocytes; Leucémie; Leukemia; Lymphocytes granuleux; Neutropenia; Neutropénie; Polyarthrite rhumatoïde; Rheumatoid arthritis; Syndrome de Felty

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center